RE:This might help clear up things a bit “Going to the global market with a goal of $500 million.” So, that’s $670 million Canadian in peak yearly revenue.
Let’s say $300 million for TH. That’s about $4 per share.
With Egrifta in place (and still growing), that is plenty of profit to support a share price much higher.
bfw
SPCEO1 wrote: Here is a press report from Taiwan on the Taimed meeting today. It seems to me this sorts out some of the things our friend from Taiwan was trying to communicate. It also looks like there are more patients than I was suggesting right now if the claims made by Taimed are accurate.
Zhongyu New Drug (4147-TW) Today (5) held a law conference to explain the operation overview. Chairman Zhang Nianyuan said that its new anti-AIDS drug TROGARZO (TB-355) has obtained the US FDA drug certificate. There are also TROGARZO intramuscular injections that are being certified in the US and Europe. It is expected to enter Europe after certification and will be able to sell and target revenue in 2020.
Zhang Nianyuan explained that Trogarzo, a new AIDS drug listed in the US, has been further incorporated into the federal AIDS drug guide, and has further obtained J-Code, which will take effect on January 1 next year and formally incorporated into the US public and private medical and health care system; using J-Code It is an important part of the standard operating procedures of the US public and private medical and health care system. It will be of great help to obtain J-Code's marketing to Trogarzo.
Zhang Nianyuan said frankly that the traditional holiday will be followed, and the willingness of patients and doctors to use new drugs will be reduced. Therefore, the fourth quarter and the first quarter of next year will not be too optimistic; but in the long run, the target is still quite clear, and the future hopes to be done. Going to the global market with a goal of $500 million.
In the progress of the drug certification, the current TROGARZO intramuscular injection type is communicating with the FDA to arrange small clinical trials. It is expected to have a drug license in the next year. In Europe, it must be carried out according to the EMA process. It is estimated that Europe will be obtained in 2019. The drug certificate will be officially launched in 2020.
Zhongyu currently has Wuxi and Zhubei plants. However, due to the small scale of Wuxi plant and some problems in operation, it is still to be clarified. Most of the production capacity is still produced in Zhubei Plant, but it is not certified by Zhubei Factory. While waiting for the certification period, all R&D operating expenses still operate as usual. Zhang Nianyuan pointed out that there is also a certain impact on the inability to turn the gross profit margin.
Zhongyu TROGARZO is the first new drug for AIDS in the past 10 years. Zhang Nianyuan emphasized that it is effective according to the continuous increase in the number of users per month after the US market. It is expected that the number of patients in the fourth quarter will increase with the penetration rate of insurance. It is increased to 450-500 people compared to 300-350 people in September.